Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock

$14.38

0.28% today

NYSE, Feb 28, 05:19 pm CET

ISIN

US8740602052

Symbol

TAK

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock price

$14.34

-3.29 18.66% 5Y

NYSE, Closing price Thu, Feb 27 2025

+0.00 0.00%

ISIN

US8740602052

Symbol

TAK

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$45.46b
Enterprise Value	$73.12b
P/E (TTM) P/E ratio	33.16
EV/FCF (TTM) EV/FCF	12.92
EV/Sales (TTM) EV/Sales	2.42
P/S ratio (TTM) P/S ratio	1.50
P/B ratio (TTM) P/B ratio	0.96
Dividend yield	4.26%
Last dividend (FY24)	$0.61
Revenue growth (TTM) Revenue growth	1.92%
Revenue (TTM) Revenue	$30.22b
EBIT (operating result TTM) EBIT	$4.07b
Free Cash Flow (TTM) Free Cash Flow	$5.66b
Cash position	$3.14b
EPS (TTM) EPS	$0.43
P/E forward	48.88
P/S forward	1.52
EV/Sales forward	2.45
Short interest	0.12%

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Get Started for Free Today

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

16 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast:

8x Buy

50%

8x Hold

50%

More details on Analyst Estimates Including Price Targets

16 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast:

Buy

50%

Hold

50%

Analyst Estimates with Stock Price Targets

Financial data from Takeda Pharmaceutical Co. Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	30,218 30,218	2% 2% 100%
- Direct Costs	14,223 14,223	1% 1% 47%
Gross Profit	15,995 15,995	3% 3% 53%
- Selling and Administrative Expenses	2,220 2,220	17% 17% 7%
- Research and Development Expense	4,694 4,694	5% 5% 16%
EBITDA	9,082 9,082	5% 5% 30%
- Depreciation and Amortization	5,008 5,008	7% 7% 17%
EBIT (Operating Income) EBIT	4,074 4,074	24% 24% 13%
Net Profit	1,364 1,364	8% 8% 5%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock News

Neutral

PRNewsWire

●

4 days ago

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult HAE Patients. In the EU, TAKHZYRO is Approved for Routine Prevention of Recurrent HAE Attacks in Pati...

Positive

Seeking Alpha

●

28 days ago

Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued

Takeda Pharmaceutical offers attractive dividends and has a low price/book ratio, making it appealing despite recent price drops and US policy uncertainties. The company reported strong Q3 earnings, raised full-year FY2025 guidance, and announced a new CEO and a significant share repurchase program. Revenue and operating income exceeded expectations due to a shortage of generic Vyvanse, favorab...

Neutral

Seeking Alpha

●

29 days ago

Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer Milano Furuta - Chief Financial Officer Andy Plump - President, R&D Conference Call Participants Stephen Barker - Jefferies Hidemaru Yamaguchi - Citi Mike Nedelc...

More Takeda Pharmaceutical Co. Ltd. Sponsored ADR News

Company Profile

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Head office	Japan
CEO	Christophe Weber
Employees	49,281
Founded	1781
Website	www.takeda.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now